Vafseo Europska Unija - hrvatski - EMA (European Medicines Agency)

vafseo

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemijski pripravci - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Revolade Europska Unija - hrvatski - EMA (European Medicines Agency)

revolade

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Lojuxta Europska Unija - hrvatski - EMA (European Medicines Agency)

lojuxta

amryt pharmaceuticals dac - lomitapide - hiperkolesterolemija - sredstva za modifikaciju lipida - lojuxta je indicirana kao dodatak prehrani low‑fat i drugih lipid‑lowering lijekova s ili bez afereze najniža gustoće lipoproteina (ldl) u odraslih bolesnika s homozigotni obiteljska hiperkolesterolemija (hofh). genetičko potvrdu hofh mora biti ispitan na mogućnosti. drugi oblici primarne гиперлипопротейнемия i sekundarni uzroci гиперхолестеринемии (e. nephrotic sindrom, hipotireoza) moraju biti isključeni.

Zelboraf Europska Unija - hrvatski - EMA (European Medicines Agency)

zelboraf

roche registration gmbh - vemurafenib - melanoma - antineoplastična sredstva - vemurafenib je indiciran u monoterapiji za liječenje odraslih bolesnika s braf-v600-mutacijskim pozitivnim neosjetljivim ili metastatskim melanomom.

Votrient Europska Unija - hrvatski - EMA (European Medicines Agency)

votrient

novartis europharm limited  - pazopanib - karcinom, stanice bubrega - antineoplastična sredstva - Почечно srpastih stanica karcinom Вотриент (ОКВ)navodi u odraslih za prvu liniju liječenja održao почечно-stanica raka (pkr) i za pacijente koji su primili do цитокиновой terapija u kasnijim fazama bolesti. sarkom mekog tkiva (its)Вотриент indiciran za liječenje odraslih bolesnika s selektivna podtipovi modernih sarkom mekog tkiva (smt), koji je dobio ranije kemoterapije za метастатической bolesti ili koji su napredovali u roku od 12 mjeseci nakon (neo)adjuvantne terapije. učinkovitost i sigurnost je samo u nekim СЦ гистологических podtipova tumora.

Lumeblue (previously known as Methylthioninium chloride Cosmo) Europska Unija - hrvatski - EMA (European Medicines Agency)

lumeblue (previously known as methylthioninium chloride cosmo)

alfasigma s.p.a. - metiltioninijev klorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Pazopanib Pharmascience 200 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pazopanib pharmascience 200 mg filmom obložene tablete

pharmascience international limited, lampousas, 1, nicosia, cipar - pazopanibklorid - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 200 mg pazopaniba u obliku pazopanibklorida